Treatment of patients with metastatic urothelial cancer „unfit“ for cisplatin treatment


MUDr. Kristýna Divišová1; MUDr. Jana Katolická, Ph.D.2; MUDr. Milan Kohoutek1

1 Onkologické oddělení, Krajská nemocnice Tomáše Bati, Zlín

2 Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno



Cisplatin-based chemotherapy is the standard first-line treatment in advanced urothelial cancers. However, more than 50 % of patients are not eligible for cisplatin. Urothelial cancer patients are of higher median age and often present with organ impairment and comorbidities. In frail patients, recommended treatment options include carboplatin or gemcitabine monotherapy, or GCa or imunotherapy if possible.


Key words

metastatic urothelial cancer, unfit to cisplatine, carboplatine, imunotherapy,



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...